Liquidity	6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity	Note 12: Liquidity As of June 30, 2022, the Company had $897,779 in operating cash and expects that our operating expenses for the next twelve months will be $840,000. Management believes the Company’s existing cash balances along with contractually obligated future funding from our current agreement with Dole are sufficient to provide the necessary liquidity to meet our obligations as they come due over the next year.

Liquidity

6 Months Ended

Jun. 30, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Note 12: Liquidity

As of June 30, 2022, the Company had $897,779 in operating cash and expects that our operating expenses for the next twelve months will be $840,000. Management believes the Company’s existing cash balances along with contractually obligated future funding from our current agreement with Dole are sufficient to provide the necessary liquidity to meet our obligations as they come due over the next year.

EVOLUTIONARY GENOMICS, INC. 10-Q